Первичная иммунная тромбоцитопения и агонисты тромбопоэтиновых рецепторов: возможности отмены лечения при достижении стабильного полного тромбоцитарного ответа

Πηγή: Клиническая онкогематология, Vol 16, Iss 4 (2024)

Θεματικοί όροι: ромиплостим, первичная иммунная тромбоцитопения, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, агонисты тромбопоэтиновых рецепторов, элтромбопаг, RC254-282, ИТП, 12. Responsible consumption, 3. Good health

Σύνδεσμος πρόσβασης: https://doaj.org/article/38293a20fe5c43f8a648ec32e617e1aa

Thrombopoietin Receptor Agonists: Clinical Use and Evaluation of Treatment Efficacy ; Агонисты тромбопоэтиновых рецепторов: клиническое применение и оценка эффективности терапии

Συγγραφείς: A. G. Solodovnikov, E. Yu. Sorokina, E. I. Morkovin, А. Г. Солодовников, Е. Ю. Сорокина, Е. И. Морковин

Πηγή: Regulatory Research and Medicine Evaluation; Том 10, № 4 (2020); 236-243 ; Регуляторные исследования и экспертиза лекарственных средств; Том 10, № 4 (2020); 236-243 ; 3034-3453 ; 3034-3062

Θεματικοί όροι: ромиплостим, thrombocytopenia, thrombopoietin receptor agonists, clinical development, romiplostim, тромбоцитопения, агонисты тромбопоэтиновых рецепторов, клиническая разработка

Περιγραφή αρχείου: application/pdf

Relation: https://www.vedomostincesmp.ru/jour/article/view/343/436; Williamson DR, Albert M, Heels-Ansdell D, Arnold DM, Lauzier F, Zarychanski R, et al. Thrombocytopenia in critically ill patients receiving thromboprophylaxis: frequency, risk factors, and outcomes. Chest. 2013;144(4):1207–15. https://doi.org/10.1378/chest.13-0121; Smock KJ, Perkins SL. Thrombocytopenia: an update. Int J Lab Hematol. 2014;36(3):269–78. https://doi.org/10.1111/ijlh.12214; Gernsheimer T, James AH, Stasi R. How I treat thrombocytopenia in pregnancy. Blood. 2013;121(1):38–47. https://doi.org/10.1182/blood-2012-08-448944; Slichter S. Relationship between platelet count and bleeding risk in thrombocytopenic patients. Transfus Med Rev. 2004;18(3):153–67. https://doi.org/10.1016/j.tmrv.2004.03.003; Gauer R, Braun MM. Thrombocytopenia. Am Fam Physician. 2012;85(6):612–22. PMID: 22534274; Меликян АЛ, Егорова ЕК, Пустовая ЕИ, Колошейнова ТИ, Володичева ЕМ, Капорская ТС и др. Промежуточные результаты эпидемиологического исследования идиопатической тромбоцитопенической пурпуры у взрослых в Российской Федерации. Гематология итрансфузиология. 2019;64(4):436–46. https://doi.org/10.35754/0234-5730-2019-64-4-436-446; Neunert C, Terrell DR, Arnold DM, Buchanan G, Cines DB, Cooper N, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829–66. https://doi.org/10.1182/bloodadvances.2019000966; Меликян АЛ, Пустовая ЕИ, Егорова ЕК, Калинина МВ, Колошейнова ТИ, Суборцева ИН и др. Дифференциальная диагностика тромбоцитопений. Онкогематология. 2017;12(1):78–87. https://doi.org/10.17650/1818-8346-2017-12-1-78-87; Рахмани АФ, Михайлова ЕА, Дубинкин ИВ, Калмыкова ОС, Галузяк ВС, Троицкая ВВ и др. Рефрактерность к трансфузиям донорских тромбоцитов у больных апластической анемией и гемобластозами. Онкогематология. 2018;13(2):62–72. https://doi.org/10.17650/1818-8346-2018-13-2-62-72; Debili N, Wendling F, Cosman D, Titeux M, Florindo C, DusanterFourt I, et al. The Mpl receptor is expressed in the megakaryocytic lineage from late progenitors to platelets. Blood. 1995;85(2):391– 401. PMID: 7529061; Li J, Xia Y, Kuter DJ. Interaction of thrombopoietin with the platelet c-mpl receptor in plasma: binding, internalization, stability and pharmacokinetics. Br J Haematol. 1999;106(2):345–56. https://doi.org/10.1046/j.1365-2141.1999.01571.x; Choi ES, Nichol JL, Hokom MM, Hornkohl AC, Hunt P. Platelets generated in vitro from proplatelet-displaying human megakaryocytes are functional. Blood. 1995;85(2):402–13. PMID: 7529062; Zauli G, Vitale M, Falcieri E, Gibellini D, Bassini A, Celeghini C, et al. In vitro senescence and apoptotic cell death of human megakaryocytes. Blood. 1997;90(6):2234–43. PMID: 9310474; Kuter DJ. Milestones in understanding platelet production: a historical overview. Br J Haematol. 2014;165(2):248–58. https://doi.org/10.1111/bjh.12781; Cwirla SE, Balasubramanian P, Duffin DJ, Wagstrom CR, Gates CM, Singer SC, et al. Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. Science. 1997;276(5319):1696–9. https://doi.org/10.1126/science.276.5319.1696; Wang B, Nichol J, Sullivan J. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther. 2004;76(6):628–38. https://doi.org/10.1016/j.clpt.2004.08.010; Shirasugi Y, Ando K, Hashino S, Nagasawa T, Kurata Y, Kishimoto Y, et al. A phase II, open-label, sequential-cohort, dose-escalation study of romiplostim in Japanese patients with chronic immune thrombocytopenic purpura. Int J Hematol. 2009;90(2):157–65. https://doi.org/10.1007/s12185-009-0361-y; Afdhal NH, Giannini EG, Tayyab G, Mohsin A, Lee J-W, Andriulli A, et al. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. N Engl J Med. 2012;367(8):716–24. https://doi.org/10.1056/NEJMoa1110709; Severinsen MT, Engebjerg MC, Farkas DK, Jensen AØ, Nørgaard M, Zhao S, et al. Risk of venous thromboembolism in patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study. Br J Haematol. 2011;152(3):360–2. https://doi.org/10.1111/j.1365-2141.2010.08418.x; Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2008;371(9610):395–403. https://doi.org/10.1016/S0140-6736(08)60203-2; Neunert C, Lim W, Crowther M, Cohen A, Solberg L, Crowther MA, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117(16):4190– 207. https://doi.org/10.1182/blood-2010-08-302984; Wong RSM, Saleh MN, Khelif A, Salama A, Portella MSO, Burgess P, et al. Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. Blood. 2017;130(23):2527–36. https://doi.org/10.1182/blood-2017-04-748707; Stanworth SJ, Estcourt LJ, Powter G, Kahan BC, Dyer C, Choo L, et al. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. N Engl J Med. 2013;368(19):1771–80. https://doi.org/10.1056/NEJMoa1212772; Stanworth SJ, Dyer C, Choo L, Bakrania L, Copplestone A, Llewelyn C, et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfus Med Rev. 2010;24(3):163–71. https://doi.org/10.1016/j.tmrv.2009.11.002; Wood EM, Hudson C, Estcourt L, Johnson R, Stanworth SJ. Risk factors for bleeding: a modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood. 2014;124(21):1551. https://doi.org/10.1182/blood.V124.21.1551.1551; Bussel JB, Kuter DJ, Pullarkat V, Lyons RM, Guo M, Nichol JL. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood. 2009;113(10):2161–71. https://doi.org/10.1182/blood-2008-04-150078; Cines DB, Wasser J, Rodeghiero F, Chong BH, Steurer M, Provan D, et al. Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia. Haematologica. 2017;102(8):1342–51. https://doi.org/10.3324/haematol.2016.161968; https://www.vedomostincesmp.ru/jour/article/view/343

Διαθεσιμότητα: https://www.vedomostincesmp.ru/jour/article/view/343
https://doi.org/10.30895/1991-2919-2020-10-4-236-243

Experience in the treatment of immune thrombocytopenia in the Department of Oncohematology of the Voronezh Regional Children’s Clinical Hospital № 1 ; Опыт лечения иммунной тромбоцитопении в отделении онкогематологии Воронежской областной детской клинической больницы № 1

Συγγραφείς: N. B. Yudina, M. V. Belyanskaya, M. A. Solovyova, G, V. Trubnikova, E. A. Ryabova, Yu. S. Ovchinnikova, E. A. Orlova, D. A. Skorobogatova, N. V. Brezhneva, S. A. Ryabova, I. L. Bykova, E. V. Sargina, A. A. Shtokalov, T. V. Stepanova, I. V. Grebennikova, Н. Б. Юдина, М. В. Белянская, М. А. Соловьева, Г. В. Трубникова, Е. А. Рябова, Ю. С. Овчинникова, Е. А. Орлова, Д. А. Скоробогатова, Н. В. Брежнева, С. А. Рябова, И. Л. Быкова, Е. В. Саргина, А. А. Штокалов, Т. В. Степанова, И. В. Гребенникова

Συνεισφορές: The study was performed without external funding., Исследование проведено без спонсорской поддержки.

Πηγή: Russian Journal of Pediatric Hematology and Oncology; Том 6, № 1 (2019); 28-38 ; Российский журнал детской гематологии и онкологии (РЖДГиО); Том 6, № 1 (2019); 28-38 ; 2413-5496 ; 2311-1267 ; 10.21682/2311-1267-2019-6-1

Θεματικοί όροι: спленэктомия, immune thrombocytopenia, pathogenesis of immune thrombocytopenia, intravenous immunoglobulins, treatment of immune thrombocytopenia, thrombopoietin receptor agonists, splenectomy, иммунная тромбоцитопения, патогенез иммунной тромбоцитопении, внутривенные иммуноглобулины, лечение иммунной тромбоцитопении, агонисты тромбопоэтиновых рецепторов

Περιγραφή αρχείου: application/pdf

Relation: https://journal.nodgo.org/jour/article/view/469/450; Румянцев А.Г., Масчан А.А., Жуковская Е.В. и др. Детская гематология. Сборник клинических рекомендаций. М.: ГЭОТАР-Медиа, 2015. С. 245–262.; Rodeghiero F., Stasi R., Gernsheimer T., Michel M., Provan D., Arnold D.M., Bussel J.B., Cines D.B., Chong B.H., Cooper N., Godeau B., Lechner K., Mazzucconi M.G., McMillan R., Sanz M.A., Imbach P., Blanchette V., Kühne T., Ruggeri M., George J.N. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009;113(11):2386–93. doi:10.1182/blood-2008-07-162503.; Terrell D.R., Beebe L.A., Vesely S.K., Neas B.R., Segal J.B., George J.N. The incidence of immune thrombocytopenic purpura in children and adults: A critical review of published reports. Am J Hematol 2010;85(3):174–80. doi:10.1002/ajh.21616.; British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 2003;120(4):574–96. PMID: 12588344. doi:10.1046/j.1365-2141.2003.04131.x.; Yenicesu I., Yetgin S., Ozyurek E., Aslan D. Virus-associated immune thrombocytopenic purpura in childhood. Pediatr Hematol Oncol 2002;19(6):433–7. doi:10.1080/08880010290097233.; Smalisz-Skrzypczyk K., Romiszewski M., Matysiak M., Demkow U., Pawelec K. The influence of primary cytomegalovirus or Epstein– Barr virus infection on the course of idiopathic thrombocytopenic purpura. Adv Exp Med Biol 2016;878:83–8. doi:10.1007/5584_2015_162.; Kossiva L., Kyriakou D., Mitsioni A., Garoufi A. Acute renal failure in a child with thrombocytopenic purpura caused by acute Epstein–Barr virus infection after treatment with anti-D immunoglobulin. Pediatr Emerg Care 2013;29(6):748–50.; Bashal F. Hematological disorders in patients with systemic lupus erythematosus. Open Rheumatol J 2013;7:87–95. doi:10.2174/1874312901307010087.; Hepburn A.L., Narat S., Mason J.C. The management of peripheral blood cytopenias in systemic lupus erythematosus. Rheumatology 2010;49(12):2243–54. doi:10.1093/rheumatology/keq269.; Bartley T.D., Bogenberger J., Hunt P., Li Y.-S., Lu H.S., Martin F., Chang M.-S., Samal B., Nichol J.L., Swift S., Johnson M.J., Hsu R.-Y., Parker V.P., Suggs S., Skrine J.D., Merewether L.A., Clogston C., Hsu E., Hokom M.M., Hornkohl A., Choi E., Pangelinan M., Sun Y., Mar V., McNinch J., Simonet L., Jacobsen F., Xie C., Shutter J., Chute H., Basu R., Selander L., Trollinger D., Sieu L., Padilla D., Trail G., Elliott G., Izumi R., Covey T., Crouse J., Garcia A., Xu W., Del Castillo J., Biron J., Cole S., Hu M.C.-T., Pacifici R., Ponting I., Saris C., Wen D., Yung Y.P., Lin H., Rosselman R.A. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell 1994;77(7):1117–24. doi:10.1016/0092-8674(94)90450-2.; Kuter D.J., Beeler D.L., Rosenberg R.D. The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production. Proc Nat Acad Sci USA 1994;91(23):11104–8. doi:10.1073/pnas.91.23.11104.; Lok S., Kaushansky K., Holly R.D., Kuijper J.L., Lofton-Day C.E., Oort P.J., Grant F.J., Heipel M.D., Burkhead S.K., Kramer J.M., Bell L.A., Sprecher C.A., Blumberg H., Johnson R., Prunkard D., Ching A.F.T., Mathewes S.L., Bailey M.C., Forstrom J.W., Buddle M.M., Osborn S.G., Evans S.J., Sheppard P.O., Presnell S.R., O’Hara P.J., Hagen F.S., Roth G.J., Foster D.C. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 1994;369(6481):565–8. doi:10.1038/369565a0.; McMillan R., Luiken G.A., Levy R., Yelenosky R., Longmire R.L. Antibody against megakaryocytes in idiopathic thrombocytopenic purpura. JAMA 1978;239(23):2460–2. doi:10.1001/jama.1978.03280500056020.; Rabellino E.M., Levene R.B., Leung L.L., Nachman R.L. Human megakaryocytes II. Expression of platelet proteins in early marrow megakaryocytes. J Exp Med 1981;154:88–100. doi:10.1084/jem.154.1.88.; Vinci G., Tabilio A., Deschamps J.F., Van Haeke D., Henri A., Guichard J., Tetteroo P., Lansdorp P.M., Hercend T., Vainchenker W., Breton‐Gorius J. Immunological study of in vitro maturation of human megakaryocytes. Br J Haematol 1984;56(4):589–605. doi:10.1111/j.1365-2141.1984.tb02184.x.; Johnsen J. Pathogenesis in immune thrombocytopenia: new insights. Hematol Am Soc Hematol Educ Program 2012;2012:306–12. doi:10.1182/asheducation-2012.1.306.; He R., Reid D.M., Jones C.E., Shulman N.R. Spectrum of Ig classes, specificities, and titers of serum antiglycoproteins in chronic idiopathic thrombocytopenic purpura. Blood 1994;83(4):1024–32. PMID: 8111044.; Gernsheimer T. Chronic idiopathic thrombocytopenic purpura: mechanisms of pathogenesis. Oncologist 2009;14:12–21. doi:10.1634/theoncologist.2008-0132.; Tomiyama Y., Kosugi S. Autoantigenic epitopes on platelet glycoproteins. Int J Hematol 2005;81(2):100–5. doi:10.1532/IJH97.04193.; Nugent D., McMillan R., Nichol J.L., Slichter S.J. Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production. Br J Haematol 2009;146:585–96. doi:10.1111/j.1365-2141.2009.07717.x.; Ikeda Y., Miyakawa Y. Development of thrombopoietin receptor agonists for clinical use. J Thromb Haemost 2009;7(Suppl 1):239–44. doi:10.1111/j.1538-7836.2009.03440.x.; Dmytrijuk A., Robie-Suh K., Rieves D., Pazdur R. Eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura. Oncology (Williston Park) 2009;23(13):1171–7. PMID: 20043468.; Yadav D.K., Tripathi A.K., Kumar A., Agarwal J., Prasad K.N., Gupta D., Singh A.K. Association of TNF-α-308G>A and TNF-β +252A>G genes polymorphisms with primary immune thrombocytopenia: a North Indian study. Blood Coagul Fibrinolysis 2016;27(7):791–6. doi:10.1097/MBC.0000000000000492.; Jamali F., Lemery S., Ayalew K., Robottom S., Robie-Suh K., Rieves D., Razdur R. Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura. Oncology (Williston Park) 2009;23(8):704–9. PMID: 19711585.; Sarpatwari A., Bussel J.B., Ahmed M., Erqou S., Semple J.W., Newland A.C., Bennett D., Pharoah P., Provan D. Single nucleotide polymorphism (SNP) analysis demonstrates a significant association of tumour necrosis factor-alpha (TNFA) with primary immune thrombocytopenia among Caucasian adults. Hematology 2011;16(4):243–8. doi:10.1179/102453311X13025568941808.; Makhlouf M.M., Abd Elhamid S.M. Expression of IL4 (VNTR intron 3) and IL10 (-627) genes polymorphisms in childhood immune thrombocytopenic purpura. Lab Med 2014;45(3):211–9. doi:10.1309/LMB0QC5T1RXTTRZQ.; Ji X., Zhang L., Peng J., Hou M. T cell immune abnormalities in immune thrombocytopenia. J Hematol Oncol 2014;7:72. doi:10.1186/s13045-014-0072-6.; Cooper N., Bussel J. The pathogenesis of immune thrombocytopaenic purpura. Br J Haematol 2006;133(4):364–74. doi:10.1111/j.1365-2141.2006.06024.x.; Zhang F., Chu X., Wang L., Zhu Y., Li L., Ma D., Peng J., Hou M. Cell-mediated lysis of autologous platelets in chronic idiopathic thrombocytopenic purpura. Eur J Haematol 2006;76(5):427–31. doi:10.1111/j.1600-0609.2005.00622.x.; Kühne T., Imbach P., Bolton-Maggs P.H., Berchtold W., Blanchette V., Buchanan G.R.; Intercontinental Childhood ITP Study Group. Newly diagnosed idiopathic thrombocytopenic purpura in childhood: an observational study. Lancet 2001;358(9299):2122–5. doi:10.1016/S0140-6736(01)07219-1.; https://journal.nodgo.org/jour/article/view/469

Διαθεσιμότητα: https://journal.nodgo.org/jour/article/view/469
https://doi.org/10.21682/2311-1267-2019-6-1-28-38

СОВРЕМЕННАЯ ТАРГЕТНАЯ ТЕРАПИЯ ИММУННОЙ ТРОМБОЦИТОПЕНИИ

Συγγραφείς: Загорулько, Олег, Марченко, Маргарита, Лямкина, Анна, Поспелова, Татьяна

Θεματικοί όροι: ИММУННАЯ ТРОМБОЦИТОПЕНИЯ, ТАРГЕТНАЯ ТЕРАПИЯ, АГОНИСТЫ ТРОМБОПОЭТИНОВЫХ РЕЦЕПТОРОВ

Περιγραφή αρχείου: text/html

Διαθεσιμότητα: http://cyberleninka.ru/article/n/sovremennaya-targetnaya-terapiya-immunnoy-trombotsitopenii
http://cyberleninka.ru/article_covers/15510688.png

Современная таргетная терапия иммунной тромбоцитопении

Πηγή: Медицина и образование в Сибири.

Θεματικοί όροι: 3. Good health, ИММУННАЯ ТРОМБОЦИТОПЕНИЯ, ТАРГЕТНАЯ ТЕРАПИЯ, АГОНИСТЫ ТРОМБОПОЭТИНОВЫХ РЕЦЕПТОРОВ

Περιγραφή αρχείου: text/html

Σύνδεσμος πρόσβασης: http://cyberleninka.ru/article_covers/15510688.png
http://cyberleninka.ru/article/n/sovremennaya-targetnaya-terapiya-immunnoy-trombotsitopenii

Опыт лечения иммунной тромбоцитопении в отделении онкогематологии Воронежской областной детской клинической больницы No 1

Θεματικοί όροι: лечение иммунной тромбоцитопении, патогенез иммунной тромбоцитопении, агонисты тромбопоэтиновых рецепторов, дети, внутривенные иммуноглобулины, intravenous immunoglobulins, иммунная тромбоцитопения, splenectomy, 3. Good health, children, immune thrombocytopenia, pathogenesis of immune thrombocytopenia, thrombopoietin receptor agonists, treatment of immune thrombocytopenia, спленэктомия